Schizophrenia News and Research

Latest Schizophrenia News and Research

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Study reveals striking brain similarities in bipolar disorder and schizophrenia

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have conducted a study which has found striking brain similarities in bipolar disorder and schizophrenia. The research has also pinpointed for the first time that a process which controls how information is transmitted from neuron to neuron in the brain is altered in both conditions and may potentially contribute to the developments of improved treatments in the future.

25 Aug 2011

Tropical plants may contain basis of new and effective treatments for ovarian cancer

Tropical plants may contain the basis of new and effective treatments for ovarian cancer, according to researchers at the Universities of Strathclyde and Portsmouth.

25 Aug 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

People admitted to hospital for mental illness more likely to experience control intervention

The use of control interventions, including physical and mechanical restraints, acute control medications and seclusion, is intended to be a method of last resort in Ontario care facilities, including hospitals.

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

Harnessing the brain’s capacity to adapt and regenerate

Understanding the brain’s capacity to adjust to physical and mental trauma and injury – and how to exploit this therapeutically to help patients – is the focus of a major international symposium at the University of New South Wales next month (8 Sept).

22 Aug 2011

FDA accepts Alexza ADASUVE NDA, assigns PDUFA action date

Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

20 Aug 2011

New Therapy Grants Program supports innovative approach to treat epilepsy

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) announced today a New Therapy Grant to potentially help those with treatment resistant epilepsy.

19 Aug 2011

Seven UC scientists receive 2011 NARSAD Grants for brain and behavior research

The Brain & Behavior Research Foundation has awarded $1.5 million in NARSAD Distinguished Investigator Grants to fund highly esteemed scientists for research on brain and behavior disorders.

19 Aug 2011

IRSF announces new Rett syndrome translational research awards

The International Rett Syndrome Foundation (IRSF) announced today that it is awarding over $650,000 to support eight cutting-edge projects that aim to accelerate translational research to develop treatments for Rett syndrome.

19 Aug 2011

Cortex second quarter net loss decreases to $356,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $356,000, or $0.00 per share, for the quarter ended June 30, 2011, compared with a net loss of approximately $2,454,000, or $0.04 per share, for the corresponding prior year period, with the difference reflecting revenues in the current year period from the Company's option agreement with Servier, France's largest privately held pharmaceutical company.

18 Aug 2011

Researchers to unravel how brain makes everyday prognostications

Every day we make thousands of tiny predictions - when the bus will arrive, who is knocking on the door, whether the dropped glass will break. Now, in one of the first studies of its kind, researchers at Washington University in St. Louis are beginning to unravel the process by which the brain makes these everyday prognostications.

18 Aug 2011

Mice with enzyme deficiency are unable to properly assess threat

Do you run when you should stay? Are you afraid of all the wrong things? An enzyme deficiency might be to blame, reveals new research in mice by scientists at the University of Southern California.

12 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

Women with depression at higher risk of stroke

A new study published this week shows that depression puts middle-aged and older women at significant risk of suffering potentially debilitating strokes.

12 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

Study suggests ways to remediate cognitive errors

Concern about the capacity of individuals with schizophrenia to consent to clinical research studies has largely focused on impairment due to psychotic symptoms associated with the disorder. Less attention has been given to the cognitive errors that prospective participants make when undergoing a formal assessment of decisional capacity.

10 Aug 2011